Evidence map›Paper›PMID 35931041›Full record

ArticleThe international journal of neuropsychopharmacology2022

Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions.

Jennifer L Phillips, Amanda Van Geel, Patricia Burhunduli, Dominique Vasudev, Lisa A Batten, Sandhaya Norris, Jeanne Talbot, Abigail Ortiz, Olabisi Owoeye, Pierre Blier

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01945047 (Phase 2 Optimization of the Antidepressant Action of Ketamine in Treatment-Resistant Depression and Investigations on Its Mechanism of Action), which is not on this map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01945047 phase2 / phase3completednot on this map

Phase 2 Optimization of the Antidepressant Action of Ketamine in Treatment-Resistant Depression and Investigations on Its Mechanism of Action

TypeinterventionalSponsorUniversity of OttawaRan2013 to 2017Enrolled46ConditionsTreatment-resistant DepressionArmsKetamine, Midazolam
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Arketamine for cognitive impairment in psychiatric disorders.European archives of psychiatry and clinical neuroscience · 2023
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jennifer L PhillipsUniversity of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Ontario, Canada.
Amanda Van GeelUniversity of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Ontario, Canada.
Patricia BurhunduliUniversity of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Ontario, Canada.
Dominique VasudevUniversity of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Ontario, Canada.
Lisa A BattenUniversity of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Ontario, Canada.
Sandhaya NorrisUniversity of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Ontario, Canada.
Jeanne TalbotUniversity of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Ontario, Canada.
Abigail OrtizUniversity of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Ontario, Canada.
Olabisi OwoeyeUniversity of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Ontario, Canada.
Pierre BlierUniversity of Ottawa Institute of Mental Health Research at The Royal, Ottawa, Ontario, Canada.
University of Ottawa · CARoyal Ottawa Mental Health Centre · CACarleton University · CACentre for Addiction and Mental Health · CA

Funding

CIHR 274324
6 · The paper itself

Abstract

backgroundSubanesthetic ketamine infusions can elicit rapid and sustained antidepressant effects, yet the potential cognitive impact of ketamine has not been thoroughly examined. This study measured changes in objective and subjective cognitive function following repeated ketamine treatment.

methodsThirty-eight patients with treatment-resistant depression were administered cognitive assessments before and after undergoing 7 i.v. ketamine infusions (0.5 mg/kg over 40 minutes) within a clinical trial examining the efficacy of single and repeated administrations. Depression severity and perceived concentration were evaluated with the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptoms Self-Report.

resultsTwenty-three participants (60.5%) responded after repeated infusions (≥50% decrease in MADRS total scores). We measured significant improvements in several cognitive domains, including attention, working memory, verbal, and visuospatial memory (effect sizes ranging from Cohen d = 0.37-0.79). Cognitive changes were attributed to reduction in depressive symptoms except for improvement in verbal memory, which remained significant after adjustment for change in MADRS total score (P = .029, η p2 = 0.13). Only responders reported improvement in subjective cognitive function with repeated ketamine administration (MADRS item 6, P < .001, d = 2.00; Quick Inventory of Depressive Symptoms Self-Report item 10, P < .001, d = 1.36).

conclusionA short course of repeated ketamine infusions did not impair neurocognitive function in patients with treatment-resistant depression. Further research is required to understand the potential mediating role of response and remission on improved cognitive function accompanying ketamine treatment as well as to examine longer-term safety outcomes. ClinicalTrials.gov identifier NCT01945047.

Indexed as

Depressive Disorder, Treatment-ResistantKetamineMajor Depressive DisorderCognitionDepressionHumansInfusions, IntravenousMemory, Short-TermTreatment OutcomeKetamineintravenous ketaminemajor depressive disorderneurocognitive functionTreatment-resistant depression

Identifiers

PMID35931041
PMCPMC9743964
OpenAlexW4290097488

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.